Company: LBRX
Filing Date: 2025-07-23
Form Type: DRS/A
Source: 0000950123-25-006557
Chunk: 262

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-07-23
Form: DRS/A
Chunk 262
---
,800 | -8 |     |           |   891,050 |
| Chief Medical Officer                       |     |      |      |     |        |         |     |        |         |     |        |           |     |              |           |    |     |           |           |

| (1) | Amounts reported in this column represent 2024 discretionary annual bonuses and, for Dr. Eramo only, an 
 additional $75,000 discretionary bonus paid in 2024.                                                    |

| (2) | Amounts reported in this column represent the aggregate grant date fair value of the stock options granted to                                                                                                                                         
 our named executive officers during 2024 under the 2023 Plan, as calculated in accordance with FASB ASC Topic 718. Assumptions used in the calculations of these amounts are included in Note 10 to our audited financial statements included in this 
 registration statement. The amounts do not reflect the actual economic value that may be realized by the named executive officer.                                                                                                                     |

| (3) | Commenced employment as our Chief Executive Officer in November 2024. |

| (4) | Amount shown represents a housing stipend. |

| (5) | Resigned as our Chief Executive Officer in December 2024. |

| (6) | Amount shown includes $13,800 in Company-paid 401(k) matching contributions and certain benefits in connection                                                                                                                             
 with Mr. Prensky’s employment termination pursuant to the Prensky Separation Agreement (as defined below), which include the following: (i) eighteen (18) months of base salary ($750,000), (ii) an amount with respect to his 2024 annual 
 bonus ($250,000), and (iii) eighteen (18) months of the Consolidated Omnibus Budget Reconciliation Act of 1985, or COBRA, premiums ($49,746).                                                                                              |

| (7) | Commenced employment as our Chief Financial Officer in June 2024 and subsequently resigned in May 2025. |

| (8) | Amount shown represents Company-paid 401(k) matching contributions. |

181

Narrative to the Summary Compensation Table

Annual Base Salary

Our named
executive officers receive a base salary to compensate them for services rendered to us. The base salary payable to each named executive officer is intended to provide a fixed component of compensation reflecting the executive’s skill set,
experience, role, and responsibilities. The base salary of our named executive